ACUTE BRONCHIOLITIS

 

ACUTE BRONCHIOLITIS

 

DEFINITION:

An acute viral syndrome of the bronchioles characterized by wheezing and respiratory distress.

EPIDEMIOLOGY:

  • incidence: 10-15/1000 (most common LRI syndrome in young kids)
  • age of onset:
    • less than 2 yrs with peak between 6-10 weeks of age
  • risk factors:
    • winter -> early spring (RSV); fall (M. pneumoniae)
    • M > F
    • high risk patients:
      • cardiopulmonary disease (CHF, CF, BPD)
      • immunocomprimised
      • trisomy 21

PATHOGENESIS:

1. Pathogens

1. Major (33%)

  • Respiratory Syncytial Virus (RSV)

2. Minor

  • adenovirus types 7 & 21
  • parainflenzae types 1 & 3
  • influenzae A & B, enterovirus
  • mycoplasma pneumoniae

2. Pathogenesis

  • The infecting virus spreads from the upper respiratory tract (prodrome) and invades the medium and small bronchi and bron-chioles resulting in an inflammatory response consisting of edema and exudate (mucous and cellular debris) and epithelial necrosis. Since resistence to the airflow is inversely related to the 4th power of the radius (Poiseuille's Law), even minor thickening of the bronchiolar wall produces a profound effect on airflow. Airway resistence in the smaller air passages increases during both inspiration and expiration but since the radius of the airway is smaller during expiration, the resulting ball-valve respiratory obstruction leads to early air trapping and overinflation. Atelectasis occurs when the obstruction becomes complete and trapped air is absorbed.
  • RSV is shed from the respiratory tract for an average of 9 days in children under 1 year of age and for up to months in infants with immunodeficiency syndromes.

DIAGNOSIS:

1. Clinical

  • age, season, clinical features

2. Laboratory

  • viral (RSV) identification

CLINICAL FEATURES:

1. Prodrome

  • mild URTI for several (1-4) days:
    • rhinitis (serous nasal discharge)
    • sneezing
    • cough
    • fever (38.5-39 C)
    • anorexia with poor feeding

2. Respiratory Manifestations

  • mild cases:
    • gradual onset and resolves within 1-3 days
    • paroxysmal wheezing cough
  • worsening signs:
    • sudden onset and protracted
    • audible wheezing
    • prolonged expiratory phase
    • widespread fine end inspiratory, early expiratory crackles
    • decreased breath sounds
    • tachypnea (60-80 b/min)
    • tachycardia (>200 b/min)
    • hypoxia +/- cyanosis
    • lethergy and apnea
    • signs/symptoms of respiratory distress

3. Complications

1. Acute

  • dehydration
  • febrile seizures
  • respiratory distress with prolonged apneic spells
  • respiratory failure
  • death (mortality rate <1% but if underlying disease this is >1%)

2. Chronic

1. RSV Bronchiolitis

  • asthma
    • strong association between proven RSV bronchiolitis and subsequent development of asthma - about 30-50% of those with RSV bronchiolitis go on to develop asthma
    • may find an increased anti-RSV IgE antibody titre during an acute RSV infection

2. Adenovirus Bronchiolitis

  • bronchiolitis obliterans (chronic bronchiolitis)
  • unilateral hyperlucent lung syndrome

4. Prognosis

1. Acute Course

  • 80% of cases will be clinically improved within 3-4 days of initial presentation (recovery usually dramatic)
  • blood gases normalize over the next 2 weeks
  • radiologic changes normalize over 9 weeks

2. Prolonged Course

  • 20% of cases will have a protracted course lasting from weeks to months
  • persistent wheezing and hyperinflation
  • abnormal gas exchange and lung function
  • some develop lobar collapse

INVESTIGATIONS:

1. Serum

1. CBC

  • WBC (5-24), may have increased PMN and bands

2. Blood Gas

  • hypoxia due to V/Q mismatch
  • metabolic acidosis (if dehydrated)

3. Others

  • lytes, BUN, creatinine (dehydration)

2. Imaging Studies

1. Chest X-Ray

  • scattered areas of consolidation, segmental collapse and/ or patchy atelectasis
  • hyperinflation - flattened diaphragms with increased AP diameter
  • peribronchial thickening
  • rule out CHF, foreign bodies, BPD, bacterial pneumonia

3. Virology

  • nasopharyngeal aspirate for RSV or other viruses
  • culture and rapid antigen detection techniques

MANAGEMENT:

  • depends upon the degree of severity:

1. Mild

  • noisy breathing with no distress
  • send home if parents are good and a close distance
  • instructions:
    • sleep in propped up position
    • cool mist humidifier
    • oral rehydration if dehydrated

2. Moderate

  • moderate respiratory distress +/- apneic spells or cyanosis
  • high risk patient
  • admit to hospital with:
    • humidified oxygen
    • saturation moniter for hypoxia
    • apnea and blood gas monitering
    • careful temperature control
    • oral/IV rehydration

3. Severe

  • severe respiratory distress or failure
  • admit to ICU:
    • intubate and ventilate for mean of 5 days
    • ribavirin

1. Humidified Oxygen

  • proposed mechanism of action:
    • relieves hypoxia, dyspnea, and cyanosis
    • decreases the insensible water loss from tachypnea
  • dose:
    • humidified 35-40% oxygen by mask or hood box

2. Ribavirin (Virazole)

  • proposed mechanism of action:
    • a synthetic antiviral agent directed against viral DNA
    • this guanine analog prevents viral replication
  • effect:
    • shortens the clinical course
    • reduces the severity of bronchiolitis if administered early in the course of the disease
  • dose:
    • continuous inhalation as a small particle mist for 12-20 hours per 24 hours for 3-5 days
  • indications:
    • see Committee on Infectious Diseases, 1987
    • high risk patients

3. Antibiotics

  • not indicated unless evidence of secondary bacterial infection:
    • clinical deterioration +/- sepsis
    • tracheal secretions positive on gram stain or C&S
    • significant increase in WBC count and left shift

4. Bronchodilators/Steriods

  • use in Bronchiolitis is controversial
  • Salbutamol 0.04 cc/kg (up to 1cc) per dose of inhalation solution diluted in 2cc normal saline q4h with q2h prn - continue to use only if effective (i.e., decreased wheezing after a treatment)

5. Experimental

  • immunotherapy - human IgG against RSV

 

 

 

Pediatric Database - ACUTE BRONCHIOLITIS

Pediatric Organization - Pedbase [at] Gmail.com